-
1
-
-
2442746018
-
-
Queensland Cancer Registry, Queensland Department of Health, Brisbane
-
Cancer in Queensland-Incidence and Mortality, 1990. Queensland Cancer Registry, Queensland Department of Health, Brisbane, 1990.
-
(1990)
Cancer in Queensland-Incidence and Mortality, 1990.
-
-
-
2
-
-
0026648694
-
Increasing incidence of cutaneous melanoma in Queensland Australia
-
McLennan R, Green AC, McLeod GRC et al. Increasing incidence of cutaneous melanoma in Queensland Australia. J. Natl Cancer. Inst. 1992; 84: 1427-32.
-
(1992)
J. Natl Cancer. Inst.
, vol.84
, pp. 1427-1432
-
-
McLennan, R.1
Green, A.C.2
Grc, M.3
-
3
-
-
0024472026
-
Malignant melanoma: A plague of our times
-
Monson JRT. Malignant melanoma: A plague of our times. Er. J. Surg. 1989; 76: 997-8.
-
(1989)
Er. J. Surg.
, vol.76
, pp. 997-998
-
-
Monson, J.R.T.1
-
4
-
-
0029924679
-
Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994
-
Giles GG, Armstrong BK, Burton RC et al. Has mortality from melanoma stopped rising in Australia? Analysis of trends between 1931 and 1994. BMJ 1996; 312: 1121-5.
-
(1996)
BMJ
, vol.312
, pp. 1121-1125
-
-
Giles, G.G.1
Armstrong, B.K.2
Burton, R.C.3
-
5
-
-
0027411123
-
Melanoma recurrence after excision: Is a wide margin justified
-
O'Rourke MGE, Altmann C. Melanoma recurrence after excision: Is a wide margin justified. Ann. Surg. 1993; 217: 2-5.
-
(1993)
Ann. Surg.
, vol.217
, pp. 2-5
-
-
Mge, O.1
Altmann, C.2
-
7
-
-
0019461784
-
A multifactorial analysis of melanoma
-
Balch CM, Soong S-J, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. Ann. Surg. 1981; 193: 377-88.
-
(1981)
Ann. Surg.
, vol.193
, pp. 377-388
-
-
Balch, C.M.1
Soong, S.-J.2
Murad, T.M.3
Ingalls, A.L.4
Maddox, W.A.5
-
9
-
-
0026802163
-
Prolongation of survival in metastatic melanoma after specific active immunotherapy with a new polyvalent melanoma vaccine
-
Morion DL, Foshag LJ, Hoon DSB et al. Prolongation of survival in metastatic melanoma after specific active immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. 1992; 216: 463-82.
-
(1992)
Ann. Surg.
, vol.216
, pp. 463-482
-
-
Morion, D.L.1
Foshag, L.J.2
Dsb, H.3
-
10
-
-
0021077073
-
A multifactorial analysis of melanoma
-
Balch C, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J. Clin. Oncol. 1983; 1: 126-34.
-
(1983)
IV. Prognostic Factors in 200 Melanoma Patients with Distant Metastases (Stage III). J. Clin. Oncol.
, vol.1
, pp. 126-134
-
-
Balch, C.1
Soong, S.J.2
Murad, T.M.3
Smith, J.W.4
Maddox, W.A.5
Durant, J.R.6
-
11
-
-
0000937789
-
Contribution to the knowledge of sarcoma
-
Coley WB. Contribution to the knowledge of sarcoma. Ann. Surg. 1891, 14: 199-220.
-
(1891)
Ann. Surg.
, vol.14
, pp. 199-220
-
-
Coley, W.B.1
-
12
-
-
0000161413
-
The treatment of malignant tumors by repeated inoculations of erysipelas; with a report of original cases
-
Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas; with a report of original cases. Am. J. Med. Sei. 1893; 105: 487-511.
-
(1893)
Am. J. Med. Sei.
, vol.105
, pp. 487-511
-
-
Coley, W.B.1
-
14
-
-
0016723594
-
An endotoxin-induced serum factor that causes necrosis of tumours
-
Carswell EA, Old LJ, Kassel S. An endotoxin-induced serum factor that causes necrosis of tumours. Proc. Natl Acad. Sei. USA 1975; 72: 3666-70.
-
(1975)
Proc. Natl Acad. Sei. USA
, vol.72
, pp. 3666-3670
-
-
Carswell, E.A.1
Old, L.J.2
Kassel, S.3
-
15
-
-
0015354459
-
Eighty years of immunotherapy: A review of immunological methods used for the treatment of human cancer
-
Currie GA. Eighty years of immunotherapy: A review of immunological methods used for the treatment of human cancer. Br. J. Cancer 1972; 26: 141-53.
-
(1972)
Br. J. Cancer
, vol.26
, pp. 141-153
-
-
Currie, G.A.1
-
16
-
-
0019773275
-
Adjuvant immunotherapy or chemotherapy for malignant melanoma
-
Fisher RI, Terry WD, Hodes RJ et al. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Surg. Clin. North Am. 1981; 61: 1267-77.
-
(1981)
Surg. Clin. North Am.
, vol.61
, pp. 1267-1277
-
-
Fisher, R.I.1
Terry, W.D.2
Hodes, R.J.3
-
17
-
-
0018934489
-
A trial of Imidazol Carboxamide in disseminated melanoma: Clinical immunological results
-
Clunie GJA, Cough IR, Drury M et al. A trial of Imidazol Carboxamide in disseminated melanoma: Clinical immunological results. Cancer 1980; 46: 475-9.
-
(1980)
Cancer
, vol.46
, pp. 475-479
-
-
Gja, C.1
Cough, I.R.2
Drury, M.3
-
18
-
-
33744845423
-
Prospective randomized trial of IL2 alone or in conjunction with LAKS for treatment of patients with advanced cancer
-
Rosenberg SA, Lotze MJ, Yang JC et al. Prospective randomized trial of IL2 alone or in conjunction with LAKS for treatment of patients with advanced cancer. J. Natl Cancer Inst. 1993; 316: 898-05.
-
(1993)
J. Natl Cancer Inst.
, vol.316
, pp. 898-905
-
-
Rosenberg, S.A.1
Lotze, M.J.2
Yang, J.C.3
-
19
-
-
0020635291
-
Lymphokine-activated killer cell phenomenon
-
Grimm EA, Robb RJ, Roth JA. et al. Lymphokine-activated killer cell phenomenon. J. Exp. Med. 1983; 158: 1356-61.
-
(1983)
J. Exp. Med.
, vol.158
, pp. 1356-1361
-
-
Grimm, E.A.1
Robb, R.J.2
Roth, J.A.3
-
21
-
-
0022871958
-
Clinical effects and toxicity of interleukin-2 in patients with cancer
-
Lotze MT, Matory YL, Rayner A A et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764-72.
-
(1986)
Cancer
, vol.58
, pp. 2764-2772
-
-
Lotze, M.T.1
Matory, Y.L.2
Rayner, A.A.3
-
22
-
-
0030030347
-
Adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Co-operative Oncology Group Trial EST 1684
-
Kirkwood JM, Strawderman MH, Ernstoff MS et al. Adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Co-operative Oncology Group Trial EST 1684. J. Clin. Oncol. 1996; 14: 7-17.
-
(1996)
J. Clin. Oncol.
, vol.14
, pp. 7-17
-
-
Kirkwood, J.M.1
Strawderman, M.H.2
Ernstoff, M.S.3
-
23
-
-
0025356521
-
Recombinant human Interferon-gamma: Adverse effects in high risk stage I and stage II cutaneous malignant melanoma
-
Meyskens FL, Kopecky K, Samson H et al. Recombinant human Interferon-gamma: Adverse effects in high risk stage I and stage II cutaneous malignant melanoma. J. Natl Cancer Inst. 1990; 82: 1071.
-
(1990)
J. Natl Cancer Inst.
, vol.82
, pp. 1071
-
-
Meyskens, F.L.1
Kopecky, K.2
Samson, H.3
-
24
-
-
0028232019
-
Early endothelium and polymorphonuclear activation and polymorphic nuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alfa (rTNF alpha)
-
Renard N, Lianard D, Lespagnard L et al. Early endothelium and polymorphonuclear activation and polymorphic nuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alfa (rTNF alpha). Int. J. Cancer 1994; 57: 656-63.
-
(1994)
Int. J. Cancer
, vol.57
, pp. 656-663
-
-
Renard, N.1
Lianard, D.2
Lespagnard, L.3
-
25
-
-
0018090573
-
Effects of corynebacterium on immunity
-
Berd D. Effects of corynebacterium on immunity. Pharmacol. Tlier. 1978; 2: 373-96.
-
(1978)
Pharmacol. Tlier.
, vol.2
, pp. 373-396
-
-
Berd, D.1
-
26
-
-
33847477802
-
Clinical application using intralesional therapy
-
Morton DL, Hunt KK, Bauer RR et al. Clinical application using intralesional therapy. In: De Vita VT, Hillman S, Rosenberg SA (eds). Biological Therapy of Cancer. Philadelphia: JB Lippincott, 1991.
-
(1991)
In: De Vita VT, Hillman S, Rosenberg SA (Eds). Biological Therapy of Cancer. Philadelphia: JB Lippincott
-
-
Morton, D.L.1
Hunt, K.K.2
Bauer, R.R.3
-
29
-
-
0029118435
-
Active specific immunotherapy of melanoma
-
Mitchell MS. Active specific immunotherapy of melanoma. Br. Med. Bull. 1995; 51: 631-46.
-
(1995)
Br. Med. Bull.
, vol.51
, pp. 631-646
-
-
Mitchell, M.S.1
-
30
-
-
0029154946
-
The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene
-
Elshami AA, Kucharczuk JC, Stekman DH. The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. 1995; 222: 290-310.
-
(1995)
Ann. Surg.
, vol.222
, pp. 290-310
-
-
Elshami, A.A.1
Kucharczuk, J.C.2
Stekman, D.H.3
-
31
-
-
0029144835
-
Gene therapy: Growing pains
-
Marshall E. Gene therapy: Growing pains. Science 1995; 269: 1050-5.
-
(1995)
Science
, vol.269
, pp. 1050-1055
-
-
Marshall, E.1
-
32
-
-
0028292602
-
Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia
-
Grossman M, Raper SE, Kozarsky K et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat. Genet. 1994; 6: 335-41.
-
(1994)
Nat. Genet.
, vol.6
, pp. 335-341
-
-
Grossman, M.1
Raper, S.E.2
Kozarsky, K.3
-
35
-
-
0027595949
-
The basic science of gene therapy
-
Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-32.
-
(1993)
Science
, vol.260
, pp. 926-932
-
-
Mulligan, R.C.1
-
36
-
-
33847473501
-
Report of TMC Development
-
Marcel T. Report of TMC Development. Paris, France: 1996.
-
(1996)
Paris
-
-
Marcel, T.1
France2
-
37
-
-
0026641562
-
Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer
-
Donahue RE, Kessler SW, Bodine D et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 1992; 176: 1125-35.
-
(1992)
J. Exp. Med.
, vol.176
, pp. 1125-1135
-
-
Donahue, R.E.1
Kessler, S.W.2
Bodine, D.3
-
38
-
-
0029146695
-
Gene therapy of metastatic cancer by in vivo retroviral gene targeting
-
Hurford RK, Dranoff G, Mulligan RC, Tepper RI. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genet. 1995; 10: 430-5.
-
(1995)
Nat. Genet.
, vol.10
, pp. 430-435
-
-
Hurford, R.K.1
Dranoff, G.2
Mulligan, R.C.3
Tepper, R.I.4
-
40
-
-
0027183869
-
Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumour activity in the human regressive melanoma
-
Mackensen A, Ferradini L, Carcelain G et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumour activity in the human regressive melanoma. Cancer Res. 1993; 53: 3569-73.
-
(1993)
Cancer Res.
, vol.53
, pp. 3569-3573
-
-
Mackensen, A.1
Ferradini, L.2
Carcelain, G.3
-
41
-
-
0029202841
-
Immunotherapy and gene therapy of cancer
-
Ettinghausen SE, Rosenberg SA. Immunotherapy and gene therapy of cancer. Adv. Surg. 1995; 28: 223-45.
-
(1995)
Adv. Surg.
, vol.28
, pp. 223-245
-
-
Ettinghausen, S.E.1
Rosenberg, S.A.2
-
42
-
-
0027538181
-
Vaccination with irradiated tumour cells engineered to secrete GM-CSF stimulates potent specific long acting tumour immunity
-
Dranoff G, Jaffe A, Lasenby P et al. Vaccination with irradiated tumour cells engineered to secrete GM-CSF stimulates potent specific long acting tumour immunity. Proc. Natl Acad. Sei. USA 1993; 90: 3539-43.
-
(1993)
Proc. Natl Acad. Sei. USA
, vol.90
, pp. 3539-3543
-
-
Dranoff, G.1
Jaffe, A.2
Lasenby, P.3
-
44
-
-
23444461024
-
How B & T cells talk to each other
-
Clark EA, Ledbetter JA. How B & T cells talk to each other. Nature 1994; 367: 425-8.
-
(1994)
Nature
, vol.367
, pp. 425-428
-
-
Clark, E.A.1
Ledbetter, J.A.2
-
45
-
-
0030029057
-
Two levels of help for B cell alloantibody production
-
Steele DJ, Laufer TM, Smiley ST et al. Two levels of help for B cell alloantibody production. J. Exp. Med. 1996; 183: 699-703.
-
(1996)
J. Exp. Med.
, vol.183
, pp. 699-703
-
-
Steele, D.J.1
Laufer, T.M.2
Smiley, S.T.3
-
46
-
-
0024325070
-
Heterogeneity of cytokine secretion patterns and functions of helper T cells
-
Mossman TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol. 1989; 46: 111-47.
-
(1989)
Adv. Immunol.
, vol.46
, pp. 111-147
-
-
Mossman, T.R.1
Coffman, R.L.2
-
47
-
-
0026518249
-
Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma
-
Hersey AP. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J. Surg. 1992; 16: 251-60.
-
(1992)
World J. Surg.
, vol.16
, pp. 251-260
-
-
Hersey, A.P.1
-
48
-
-
0028344535
-
Tumour antigens recognised by T lymphocytes
-
Boon T, Cerottini JC, van der Eynde B, van der Bruggen P, van Pel A. Tumour antigens recognised by T lymphocytes. Ann. Rev. Immunol. 1994; 12: 337-65.
-
(1994)
Ann. Rev. Immunol.
, vol.12
, pp. 337-365
-
-
Boon, T.1
Cerottini, J.C.2
Van Der Eynde, B.3
Van Der Bruggen, P.4
Van Pel, A.5
-
49
-
-
0026322151
-
A gene encoding an antigen recognised by cytolytic T lymphocytes in human melanoma
-
van der Bruggen P, Traversai C, Chomez P et al. -A gene encoding an antigen recognised by cytolytic T lymphocytes in human melanoma. Science 1991; 254: 1643-4.
-
(1991)
Science
, vol.254
, pp. 1643-1644
-
-
Bruggen, P.1
Traversai, C.2
Chomez, P.3
-
50
-
-
0029875237
-
Melanoma peptides as vaccines
-
Hersey P. Melanoma peptides as vaccines. Today's Life Sei. 1996; 8: 34-8.
-
(1996)
Today's Life Sei.
, vol.8
, pp. 34-38
-
-
Hersey, P.1
-
51
-
-
0028967430
-
Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol
-
Grabbe S, Beisseert S, Schwarz T et al. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol. Today 1995; 16: 117-21.
-
(1995)
Today
, vol.16
, pp. 117-121
-
-
Grabbe, S.1
Beisseert, S.2
Schwarz, T.3
-
52
-
-
0029642252
-
Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
-
Marchand M, Weynants P, Rankin E et al. Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer 1995; 63: 883-5.
-
(1995)
Int. J. Cancer
, vol.63
, pp. 883-885
-
-
Marchand, M.1
Weynants, P.2
Rankin, E.3
-
53
-
-
0026813323
-
The immunotherapy and gene therapy of cancer
-
Rosenberg SA. The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 1992; 10: 180-99.
-
(1992)
J. Clin. Oncol.
, vol.10
, pp. 180-199
-
-
Rosenberg, S.A.1
-
54
-
-
0025764737
-
Immunization with haptenized autologous tumour cells induces inflammation of human melanoma métastases
-
Berd D. Immunization with haptenized autologous tumour cells induces inflammation of human melanoma métastases. Cancer Res. 1991; 51: 2731-4.
-
(1991)
Cancer Res.
, vol.51
, pp. 2731-2734
-
-
Berd, D.1
-
55
-
-
0027309489
-
High efficiency gene transfer into primary human tumor expiants without cell selection
-
Jaffee E, Dranof G, Cohen L et al. High efficiency gene transfer into primary human tumor expiants without cell selection. Cancer Res. 1993; 53: 2221-6.
-
(1993)
Cancer Res.
, vol.53
, pp. 2221-2226
-
-
Jaffee, E.1
Dranof, G.2
Cohen, L.3
-
57
-
-
0012201556
-
-
factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol. Immimother. 1997; 44: 10-20.
-
(1997)
Immimother.
, vol.44
, pp. 10-20
-
-
Immunol, C.1
-
58
-
-
85177015583
-
Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class H-restricted T cells
-
Query J, Adorini L. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class H-restricted T cells. J. Immunol. 1995; 154: 526-44.
-
(1995)
J. Immunol.
, vol.154
, pp. 526-544
-
-
Query, J.1
Adorini, L.2
-
59
-
-
0028366053
-
Frequency analysis of tumour-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumour cells
-
Herr W, Wolfel T, Heike M et al. Frequency analysis of tumour-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumour cells. Cancer Immunol. Immimother. 1994; 39: 93-9.
-
(1994)
Cancer Immunol. Immimother.
, vol.39
, pp. 93-99
-
-
Herr, W.1
Wolfel, T.2
Heike, M.3
-
60
-
-
0028967430
-
Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol
-
Grabbe S, Beissert S, Schwanz T et al. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol. Today 1995; 16: 117-21.
-
(1995)
Today
, vol.16
, pp. 117-121
-
-
Grabbe, S.1
Beissert, S.2
Schwanz, T.3
-
61
-
-
0028793675
-
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
-
Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1995; 1: 1297-1302.
-
(1995)
Nat. Med.
, vol.1
, pp. 1297-1302
-
-
Mayordomo, J.I.1
Zorina, T.2
Storkus, W.J.3
-
62
-
-
0030070340
-
Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity
-
Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 1996; 183: 7-11.
-
(1996)
J. Exp. Med.
, vol.183
, pp. 7-11
-
-
Young, J.W.1
Inaba, K.2
-
63
-
-
0028019398
-
Microsatellite instability: Marker of a mutator phenotype in cancer
-
Loeb LA. Microsatellite instability: Marker of a mutator phenotype in cancer. Cancer Res. 1994; 54: 5059-63.
-
(1994)
Cancer Res.
, vol.54
, pp. 5059-5063
-
-
Loeb, L.A.1
-
65
-
-
0029057043
-
Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical reserve
-
Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical reserve. Immunol. Today 1995; 16: 487-94.
-
(1995)
Immunol. Today
, vol.16
, pp. 487-494
-
-
Ferrone, S.1
Marincola, F.M.2
-
66
-
-
0028347925
-
Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma
-
Chen Q, Daniel V, Maher DW et al. Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer 1994; 56: 755-60.
-
(1994)
Int. J. Cancer
, vol.56
, pp. 755-760
-
-
Chen, Q.1
Daniel, V.2
Maher, D.W.3
-
67
-
-
10544232277
-
Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
-
Hahne M, Rimoldi D, Schröter M et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996; 274: 1363-6.
-
(1996)
Science
, vol.274
, pp. 1363-1366
-
-
Hahne, M.1
Rimoldi, D.2
Schröter, M.3
-
68
-
-
33847470017
-
The labyrinthine ways of cancer immunotherapy: T cell, tumour cell encounter: 'How do I lose thee? Let me count the ways.' Adv
-
Ellem KAO, Schmidt CW, O'Rourke MGE et al. The labyrinthine ways of cancer immunotherapy: T cell, tumour cell encounter: 'How do I lose thee? Let me count the ways.' Adv. Cancer Res. (in press).
-
Cancer Res. (In Press).
-
-
Kao, E.1
Schmidt, C.W.2
Mge, O.3
|